Nov. 4, 2022— Today marks the 30th anniversary of the enactment of the 340B drug pricing program. With his signature on Nov. 4, 1992, President George H.W. Bush completed a bipartisan effort in Congress to protect the health care safety net and boost care for people living with low incomes. The new program was unusual in that it did not ask the American taxpayers to provide … [Read more...]
Diabetes Care Bears the Brunt of Drugmakers’ 340B Restrictions
Sept. 23, 2021– The eight pharmaceutical companies that are restricting the discounts they offer through the 340B drug pricing program are blocking safety-net hospitals’ access to savings on a wide range of prescription drugs. But perhaps in no area is this more evident than when looking at the prices of diabetes drugs and the levels of lost 340B resources that otherwise would … [Read more...]
Research Highlights the Toll of Drug Maker Attacks on 340B, Shows How Hospitals Use Their Savings to Care for Patients
March 23, 2021– Newly released research demonstrates how patients benefit from the 340B drug pricing program in the form of expanded access and improved health outcomes. But there is growing evidence that the actions of six drug companies to cut off 340B discounts for certain drugs is sapping needed resources during the continued COVID-19 pandemic. 340B Health’s annual … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]
New Report Misses the Mark on 340B Program
November 19, 2019– The latest report from AIR340B, a group financed and backed by the pharmaceutical industry, again misrepresents the 340B drug pricing program and its long history of helping hospitals stretch scarce resources to better serve low-income and rural patients. As part of its efforts to sharply restrict 340B, the group misleads policymakers and the public by … [Read more...]